Genmab Feed

2025-09-09 20:57:27 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1769,00 DKK | +0,57% | 256 MDKK

2025-09-09 20:54:21 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1769,00 DKK | +0,57% | 256 MDKK

2025-09-03 14:30:00 Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 1737,00 DKK | +5,15% | 374 MDKK

2025-08-26 15:31:56 Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference 1577,50 DKK | +0,19% | 650 MDKK

2025-08-26 14:00:00 Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) 1577,50 DKK | +0,19% | 650 MDKK

2025-08-12 20:36:17 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1437,50 DKK | +3,87% | 183 MDKK

2025-08-07 17:08:56 Genmab Announces Financial Results for the First Half of 2025 1382,00 DKK | -4,46% | 421 MDKK

2025-08-07 16:30:00 Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) 1446,50 DKK | +5,05% | 200 MDKK

2025-07-16 12:29:46 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 1406,50 DKK | +3,34% | 216 MDKK

2025-07-01 14:00:00 Genmab Announces Changes to its Executive Committee 1314,50 DKK | -0,04% | 106 MDKK

2025-06-30 15:30:02 Completion of Share Buy-back Program 1315,00 DKK | +0,42% | 115 MDKK

2025-06-23 14:19:30 Transactions in Connection with Share Buy-back Program 1353,00 DKK | -1,74% | 148 MDKK

2025-06-17 19:34:50 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1416,50 DKK | -1,70% | 173 MDKK

2025-06-17 17:37:58 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1416,50 DKK | -1,70% | 173 MDKK

2025-06-16 15:28:44 Transactions in Connection with Share Buy-back Program 1474,50 DKK | -0,44% | 145 MDKK

2025-06-15 11:00:00 Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

2025-06-12 19:08:02 Grant of Restricted Stock Units and Warrants to Employees in Genmab 1481,00 DKK | -0,20% | 154 MDKK

2025-06-10 13:23:10 Transactions in Connection with Share Buy-back Program 1495,00 DKK | +3,42% | 254 MDKK

2025-06-02 20:30:00 Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial 1403,00 DKK | -1,44% | 230 MDKK

2025-06-02 14:03:43 Transactions in Connection with Share Buy-back Program 1423,50 DKK | +3,19% | 438 MDKK

2025-05-27 15:55:15 Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference 1394,00 DKK | +1,49% | 216 MDKK

2025-05-26 14:30:00 Transactions in Connection with Share Buy-back Program 1373,50 DKK | +0,99% | 85,1 MDKK

2025-05-22 23:05:00 Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting 1360,00 DKK | -2,68% | 235 MDKK

2025-05-21 16:02:49 Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference 1375,00 DKK | +2,69% | 288 MDKK

2025-05-20 18:01:33 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1375,00 DKK | +2,69% | 288 MDKK

2025-05-19 15:08:45 Transactions in Connection with Share Buy-back Program 1320,00 DKK | -0,08% | 223 MDKK

2025-05-14 16:15:00 Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress 1295,50 DKK | +2,01% | 242 MDKK

2025-05-12 14:51:13 Transactions in Connection with Share Buy-back Program 1320,00 DKK | +0,08% | 441 MDKK

2025-05-08 17:01:00 Genmab Announces Financial Results for the First Quarter of 2024 1319,00 DKK | +2,25% | 419 MDKK

2025-05-05 14:23:40 Transactions in Connection with Share Buy-back Program 1429,50 DKK | +0,56% | 155 MDKK

2025-05-02 02:14:27 Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) 1421,50 DKK | +1,61% | 239 MDKK

2025-04-28 14:16:53 Transactions in Connection with Share Buy-back Program 1350,00 DKK | +0,22% | 141 MDKK

2025-04-22 13:23:29 Transactions in Connection with Share Buy-back Program 1298,00 DKK | +0,50% | 260 MDKK

2025-04-15 12:22:13 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 1293,00 DKK | +1,49% | 428 MDKK

2025-04-14 14:42:57 Transactions in Connection with Share Buy-back Program 1274,00 DKK | +4,00% | 291 MDKK

2025-04-10 18:20:20 Genmab A/S Share Capital Reduction 1225,00 DKK | +0,66% | 272 MDKK

2025-04-07 13:43:11 Transactions In Connection with Share Buy-back Program 1234,00 DKK | -1,40% | 344 MDKK

2025-04-01 21:53:44 Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons 1275,50 DKK | -2,34% | 312 MDKK

2025-03-31 17:20:00 TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer 1306,00 DKK | -2,54% | 310 MDKK

2025-03-31 14:18:41 Transactions in connection with share buy-back program 1340,00 DKK | -1,76% | 293 MDKK

2025-03-27 13:00:00 TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy 1399,00 DKK | +3,17% | 323 MDKK

2025-03-25 22:28:20 Genmab Announces Initiation of Share Buy-Back Program 1356,00 DKK | +2,57% | 307 MDKK

2025-03-22 04:29:02 Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

2025-03-17 17:19:00 Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer 1389,00 DKK | -0,75% | 239 MDKK

2025-03-12 19:19:48 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1367,00 DKK | -0,40% | 238 MDKK

2025-03-12 19:13:15 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab 1367,00 DKK | -0,40% | 238 MDKK

2025-03-12 15:23:30 Passing of Genmab A/S’ Annual General Meeting 1372,50 DKK | -0,69% | 308 MDKK

2025-03-10 15:13:22 Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 1522,00 DKK | -8,29% | 860 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Genmab

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden